Pages that link to "Q53538324"

The following pages link to European multicenter study on propionyl-L-carnitine in intermittent claudication. (Q53538324):

Displaying 44 items.

• Propionyl-L-carnitine for intermittent claudication (Q24201080) (← links)
• Pharmacological interventions for peripheral artery disease (Q28218976) (← links)
• Pharmacotherapy of intermittent claudication (Q33424772) (← links)
• Long-term survival after initial hospital admission for peripheral arterial disease in the lower extremities (Q33498124) (← links)
• Risk assessment for carnitine (Q33998433) (← links)
• Propionyl-L-carnitine improves endothelial function, microcirculation and pain management in critical limb ischemia (Q34398664) (← links)
• L-propionyl-carnitine protects tissues from ischaemic injury in an 'in vivo' human ischaemia-reperfusion model (Q34547017) (← links)
• Intermittent claudication: pharmacoeconomic and quality-of-life aspects of treatment (Q34585229) (← links)
• Critical update for the clinical use of L-carnitine analogs in cardiometabolic disorders. (Q34772905) (← links)
• Pharmacotherapy for peripheral arterial disease: emerging therapeutic options (Q35015565) (← links)
• Management of intermittent claudication (Q35020304) (← links)
• Metabolic modulation and optimization of energy consumption in heart failure (Q35106491) (← links)
• Pharmacologic treatment for intermittent claudication (Q35113274) (← links)
• Drug treatment of intermittent claudication (Q35838378) (← links)
• Medical management of intermittent claudication (Q35920953) (← links)
• The role of nutrition in the management of lower extremity wounds (Q36110271) (← links)
• Does nutrition have a role in peripheral vascular disease? (Q36392251) (← links)
• Established and evolving medical therapies for claudication in patients with peripheral arterial disease (Q36633987) (← links)
• Review of mortality and cardiovascular event rates in patients enrolled in clinical trials for claudication therapies (Q36731233) (← links)
• Optimal assessment of baseline treadmill walking performance in claudication clinical trials (Q36872330) (← links)
• Peripheral artery disease: therapeutic advances (Q37134500) (← links)
• Pharmacologic therapy for intermittent claudication (Q37461418) (← links)
• Treatment strategies for peripheral artery disease (Q37519704) (← links)
• Propionyl l-carnitine: intermittent claudication and peripheral arterial disease (Q37614555) (← links)
• Pharmacological effects and clinical applications of propionyl-L-carnitine. (Q37869187) (← links)
• Medical Management of the Patient with Intermittent Claudication (Q37908726) (← links)
• Perspectives on Optimizing Trial Design and Endpoints in Peripheral Arterial Disease: A Case for Imaging-Based Surrogates as Endpoints of Functional Efficacy (Q37908732) (← links)
• Medical management for chronic atherosclerotic peripheral arterial disease (Q38050495) (← links)
• A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication (Q38074225) (← links)
• Intermittent claudication: new targets for drug development (Q38115205) (← links)
• Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial (Q38522489) (← links)
• Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication (Q40646131) (← links)
• Propionyl-L-carnitine improves exercise performance and functional status in patients with claudication (Q43623823) (← links)
• Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication (Q44123397) (← links)
• Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease (Q44416932) (← links)
• Levo-propionyl-carnitine improves the effectiveness of supervised physical training on the absolute claudication distance in patients with intermittent claudication (Q46719211) (← links)
• Effect of propionylcarnitine on changes in endothelial function and plasma levels of adhesion molecules induced by acute exercise in patients with intermittent claudication (Q46976511) (← links)
• Propionyl-L-carnitine reduces proliferation and potentiates Bax-related apoptosis of aortic intimal smooth muscle cells by modulating nuclear factor-kappaB activity (Q48082727) (← links)
• L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trial (Q48439211) (← links)
• Effect of Propionyl-L-carnitine on a Background of Monitored Exercise in Patients With Claudication Secondary to Peripheral Artery Disease (Q48786086) (← links)
• Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study (Q51792444) (← links)
• Intermittent Claudication (Q73849177) (← links)
• [Advances in the medical and minimally invasive treatment of chronic ischemia of lower limbs] (Q78784681) (← links)
• Propionyl-L-Carnitine versus Pentoxifylline : Improvement in Walking Capacity in Patients with Intermittent Claudication (Q85893680) (← links)